# A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

> **NCT04551352** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 20 (actual)

## Conditions studied

- Cutaneous Melanoma
- Uveal Melanoma
- Mucosal Melanoma

## Interventions

- **DRUG:** RO7293583
- **DRUG:** Tocilizumab
- **DRUG:** Obinutuzumab
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT04551352
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-28
- **Primary completion:** 2022-07-28
- **Final completion:** 2022-07-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551352, "A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04551352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*